Fudan University: Ovarian Neoplasms trials
The registry lists 13 Ovarian Neoplasms studies with Fudan University as lead sponsor. 11 are open to participants now and 0 have results posted.
Phase 2 6Phase 3 2No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian CancerRecruitingNCT07783022
- Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07663513Phase 2
- Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian CancerNot yet recruitingNCT07117877Phase 2
- Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
- Exosome-based Recurrence Score for Post-Treatment Ovarian CancerNot yet recruitingNCT06925126
- Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingNCT06552858Phase 2
- Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance PatientsNot yet recruitingNCT06544460Phase 2
- Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )RecruitingNCT06249308
- Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian CancerNot yet recruitingNCT05976932
- Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian CancerRecruitingNCT05446545
- Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)RecruitingNCT04520074Phase 3
- The Efficacy and Safety of The Fuzuloparib Combination With BevacizumabStatus unknownNCT05819060Phase 2
- Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian CancerStatus unknownNCT05371301Phase 3